Research And Markets Research And Markets
0 CHECKOUT

Generic and Biosimilar Pharmaceuticals (Global) - Industry Report

  • ID: 1086407
  • September 2016
  • Region: Global
  • 1460 Pages
  • Plimsoll Publishing Ltd
1 of 4

The Generic and Biosimilar Pharmaceuticals (Global) Analysis provides a detailed overview of the UK Generic and Biosimilar Pharmaceuticals (Global) market and delivers a comprehensive individual analysis on the top 1290 companies, including PFIZER INC, BRISTOL-MYERS SQUIBB COMPANY and VALEANT PHARMACEUTICALS INTERNATIONAL, INC..

This report includes a wealth of information on the financial trends over the past four years.

The latest Generic and Biosimilar Pharmaceuticals (Global) analysis is ideal for anyone wanting to:

- See the market leaders
- Identify companies heading for failure
- Seek out the most attractive acquisition
- Analyse industry trends
- Benchmark their own financial performance

Using exclusive methodology, a quick glance of this Generic and Biosimilar Pharmaceuticals (Global) report will tell you that 160 companies have a declining Plimsoll financial rating, while 161 have shown good sales growth.

Each of the largest 1290 companies is meticulously scrutinised in a single paged individual assessment and is analysed using the most up-to-date and current financial data.

Every business is examined on the following features:

- The Plimsoll Chart: A graphical assessment of a company’s financial performance

- Four year assessment of the profit/loss and balance sheet
- A written summary highlighting key performance issues

Subsequently, you will receive a thorough 100-page market analysis highlighting the latest changes in the Generic and Biosimilar Pharmaceuticals (Global) market.

This section includes:

- Best Trading Partners
- Sales Growth Analysis
- Profit Analysis
- Market Size
- Rankings

Note: Product cover images may vary from those shown
2 of 4

The Generic and Biosimilar Pharmaceuticals (Global) analysis is the most definitive and accurate study of the Generic and Biosimilar Pharmaceuticals (Global) sector in 2016.

The report is split into two sections and uses both a written and graphical analysis - analysing the 1290 largest Generic and Biosimilar Pharmaceuticals (Global) companies.

The Generic and Biosimilar Pharmaceuticals (Global) report contains the most-up-to-date financial data and Plimsoll applies these figures to create their unique and authoritative analysis.

Indeed, the first section thoroughly scrutinises the market and this section includes the following:

- Best Trading Partners: These are companies that are winning in both sales and financial strength - for example BEIJING TONGRENTANG CO., LTD. has been ranked as a best trading partner in the industry.
- Sales Growth Analysis: This section reviews the fastest growing and fastest shrinking company - for example FRESENIUS KABI AKTIENGESELLSCHAFT is among the fastest growing.
- Profit Analysis - Analysis of gross profit and pre-tax profit over the last ten years and a profitability summary comparing profits in the industry against small, medium and large companies.
- Market Size: Based on the largest 1290 companies, this is a comparison between last year's market size and the most current figure (This year the market has increased by 1.0%).
- Rankings: The top 50 companies ranked by: Market Share, Sales Growth, Gross Profit and Pre-tax Profit.

The next section focuses on company analysis and provides an in-depth analysis of the largest companies within the Generic and Biosimilar Pharmaceuticals (Global) industry.

Each business is analysed using Plimsoll’s unequivocal model and culminates in the production of the Plimsoll Chart. The Model uses a series of charts to graphically analyse an individual company and measure its ability to achieve sales growth while maintaining financial strength.

The Plimsoll Chart is a quick and dependable method of analysing a company’s financial well-being. It’s simple to understand: a rising line is good news and a falling line is bad news.

Therefore, this company analysis will tell you if a company is:

- Strong or heading for failure
- Utilising their investments
- Becoming burdened by debt
- Getting the most from their resources

The Generic and Biosimilar Pharmaceuticals (Global) analysis also provides you with full business name and address, name and ages of directors and registration address.

Note: Product cover images may vary from those shown
3 of 4

Despite the Global Generic Pharmaceutical industry becoming increasingly competitive there are 42 vibrant companies across the World exploiting innovative, more profitable routes to market. It is important therefore, for established companies such as yours, to keep up with developments.

Just published the Plimsoll Global Analysis – Generic Pharmaceuticals is comprehensive review of the World’s 200 largest Generic Pharmaceuticals. Each company is individually assessed on their latest performance to highlight everything you need to know about your marketplace in one convenient report. Some of the latest findings include:

? 42 companies are increasing sales and making a profit.
? 21 companies continue to sell at a loss for a second consecutive year.
? 80 companies have experienced a fall in their overall financial strength.
? 16 companies look ripe for takeover with sales increasing but profits negative a more prudent management being necessary.

The report delivers an instant verdict on each company using an uncomplicated written and graphical summary in one language and monetary currency. In addition, a new 100 page industry review is now also included highlighting the changing dynamics of your market.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db